Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 29 recruiting now full pipeline #130 of 28,707 conditions

Attention Deficit Hyperactivity Disorder: full-pipeline trial registry

29 of 103 indexed Attention Deficit Hyperactivity Disorder trials are currently recruiting.

Corpus placement: #130 of 28,707 conditions by registered trial count.

103 US clinical trials · 29 currently recruiting · #130 of 28,707 conditions by registered trial count

Attention Deficit Hyperactivity Disorder: 103 US clinical trials tracked, 29 recruiting.

Attention Deficit Hyperactivity Disorder is the subject of 103 registered US clinical trials on ClinicalTrials.gov, 29 of them currently open to new participants. 27 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 9 of these trials.

Enrollment posture brief

Registry condition attention-deficit-hyperactivity-disorder

OPEN 29 | RECR 28% | LATE 27 | EARLY 24 | RANK #130 | SPON 9

Nearest open-share peer: Astigmatism (28% recruiting · 32 trials)

Amyotrophic Lateral Sclerosi45.6%Mantle Cell Lymphoma44.7%Chronic Kidney Disease31.1%Attention Deficit Hypera (th…28%Metabolic Syndrome26.9%
Open-enrollment share among volume-matched conditions near Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder lists 29 open slots (28% of 103 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Attention Deficit Hyperactivity Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Attention Deficit Hyperactivity Disorder is recruiting below its size-band peers.

    29 of 103 indexed trials (28.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Attention Deficit Hyperactivity Disorder trials is spread across many organizations.

    Massachusetts General Hospital accounts for 9 of 103 trials (8.7%). 64 distinct sponsors appear on at least one study for this condition label.

  3. Typical Attention Deficit Hyperactivity Disorder enrolment sits around 71 participants.

    Median target enrolment is 71 among the 103 trials that report a genuine target (sentinel values excluded). 56 of those (54.4%) plan for fewer than 100 participants.

  4. Attention Deficit Hyperactivity Disorder research is mostly interventional.

    97 interventional and 6 observational studies make up this index (94.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 18Phase 216Phase 310Phase 417

Open and recent trials

103 total, page 2 of 3

COMPLETED Phase 3 230 participants

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

Rhodes Pharmaceuticals, L.P.

NCT01239030

COMPLETED Phase 2 227 participants

Investigating the Effect of Vortioxetine in Adult ADHD Patients

H. Lundbeck A/S

NCT02327013

COMPLETED Phase 2 221 participants

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Abbott

NCT00391729

COMPLETED NA 211 participants

Enhancing IEPs of Children With ADHD Using Daily Report Cards

State University of New York at Buffalo

NCT03747887

COMPLETED NA 206 participants

Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant

Akili Interactive Labs

NCT03649074

COMPLETED NA 187 participants

Parent Training for Attention Deficit Hyperactivity Disorder (ADHD) Preschoolers

NYU Langone Health

NCT01320098

COMPLETED NA 186 participants

Multisite Study of High School-based Treatment for Adolescents With ADHD

Ohio University

NCT04480346

COMPLETED Phase 2 141 participants

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

AbbVie (prior sponsor, Abbott)

NCT00443391

COMPLETED Phase 3 125 participants

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

Ironshore Pharmaceuticals and Development

NCT02493777

COMPLETED Phase 3 120 participants

Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment

Cephalon

NCT00343811

COMPLETED NA 117 participants

Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD

New York State Psychiatric Institute

NCT01415440

COMPLETED NA 113 participants

Helping College Students With ADHD Lead Healthier Lifestyles

University of Maryland, College Park

NCT02829970

COMPLETED Phase 4 105 participants

Bupropion for ADHD in Adolescents With Substance Use Disorder

University of Colorado, Denver

NCT00936299

COMPLETED NA 85 participants

New Technologies to Help Manage ADHD

Children's Hospital Medical Center, Cincinnati

NCT02390791

COMPLETED NA 84 participants

Cognitive ADHD Videogame Exploratory Study

Akili Interactive Labs

NCT01943539

COMPLETED NA 73 participants

dHealth Solution for Improving Parent Adherence to Behavioral Treatment for ADHD

University of California, San Francisco

NCT04025814

COMPLETED Phase 4 71 participants

Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials

Massachusetts General Hospital

NCT01063153

COMPLETED NA 70 participants

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

Denver Health and Hospital Authority

NCT00399763

COMPLETED Phase 2 69 participants

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

Aevi Genomic Medicine, LLC, a Cerecor company

NCT03265119

COMPLETED Early Phase 1 68 participants

Mindfulness-Based ADHD Treatment for Children: a Feasibility Study

Yale University

NCT04737512

COMPLETED Phase 4 62 participants

A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall

NYU Langone Health

NCT00468143

COMPLETED Phase 4 62 participants

Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD

Eli Lilly and Company

NCT00485875

COMPLETED NA 59 participants

Brain Plasticity Underlying Acquisition of New Organizational Skills in Children

NYU Langone Health

NCT04108273

COMPLETED Phase 4 50 participants

Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate

Massachusetts General Hospital

NCT00302406

COMPLETED NA 44 participants

Mindful Parenting and Parent Training Program Study

New York University

NCT03796663

COMPLETED NA 42 participants

Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase

NYU Langone Health

NCT03148782

COMPLETED Early Phase 1 40 participants

Eye Tracking as a Predictor of Methylphenidate Response in Autism With ADHD

Children's Hospital Medical Center, Cincinnati

NCT02874690

COMPLETED Phase 4 40 participants

Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)

NYU Langone Health

NCT01070394

COMPLETED NA 40 participants

A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders

University of Nebraska

NCT03730194

COMPLETED 38 participants

Attention-Deficit/Hyperactivity Disorder (ADHD) Brain Activity Changes to Psychostimulants

Hartford Hospital

NCT01310439

COMPLETED NA 38 participants

Transcranial Photobiomodulation Therapy for the Treatment of Autistic Traits in Children and Adolescents With ADHD

Massachusetts General Hospital

NCT04569058

COMPLETED Phase 2 38 participants

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

NYU Langone Health

NCT02635035

COMPLETED Phase 4 36 participants

Study of Medication Patch to Treat Children Ages 6-12 With ADHD

Massachusetts General Hospital

NCT00586157

COMPLETED NA 35 participants

Text Messaging Adherence to Stimulant Medication

Massachusetts General Hospital

NCT01967485

COMPLETED NA 34 participants

Mobile Behavioral Parent Training for Childhood ADHD: A Micro-randomized Trial

Florida International University

NCT06012851

COMPLETED Phase 2 33 participants

Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder

New York State Psychiatric Institute

NCT02803229

COMPLETED Phase 2 32 participants

A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

NCT00566449

COMPLETED Phase 2 30 participants

Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)

University of Cincinnati

NCT00414921

COMPLETED Phase 4 30 participants

Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory

Children's Hospital of Philadelphia

NCT00530257

COMPLETED Phase 4 30 participants

Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine

Neurology Group of Bergen County, P.A.

NCT01146002

COMPLETED NA 28 participants

Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01

Akili Interactive Labs

NCT03844269

COMPLETED Phase 1 28 participants

Task-Based Grounding Program

Dartmouth-Hitchcock Medical Center

NCT04648553

COMPLETED NA 28 participants

Effects of Exercise Intensity on ADHD Symptoms

Kent State University

NCT06753253

COMPLETED Early Phase 1 24 participants

Oxytocin and Cognitive Control in Adult ADHD

Massachusetts General Hospital

NCT03136263

COMPLETED NA 22 participants

Effectiveness Study of Videoconferencing on Teaching Parent Training Skills to Parents of Children With Attention Deficit Hyperactivity Disorder (ADHD)

University of California, Davis

NCT01161719

COMPLETED NA 21 participants

GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs

CogCubed

NCT01808066

COMPLETED Phase 2 20 participants

Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa

Chelsea Therapeutics

NCT00983814

COMPLETED NA 18 participants

Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices in Adults

CogCubed

NCT02127931

COMPLETED Phase 1 18 participants

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Shire

NCT01010750

COMPLETED Phase 3 16 participants

A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms

University of Oklahoma

NCT00541346

← Previous Page 2 of 3 Next →

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 16
Phase 3 10
Phase 4 17

Named interventions

Most-linked intervention names on Attention Deficit Hyperactivity Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
20 trials
Methylphenidate Drug
4 trials
Placebo Other
3 trials
Methylphenidate Transdermal System Drug
2 trials
ABT-089 Drug
2 trials
AKL-T01 Device
2 trials
Lisdexamfetamine Drug
2 trials
Daily Report Card Behavioral
2 trials

US sites by state

Facility locations filed on Attention Deficit Hyperactivity Disorder trials. A trial with sites in several states counts in each.

New York 25 trials
California 25 trials
Florida 23 trials
Ohio 16 trials
Massachusetts 15 trials
Pennsylvania 13 trials
Texas 12 trials
Arkansas 11 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Attention Deficit Hyperactivity Disorder page

103 registered trials, 29 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 29 Attention Deficit Hyperactivity Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Massachusetts General Hospital sponsors the most Attention Deficit Hyperactivity Disorder trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Attention Deficit Hyperactivity Disorder condition card totals 103 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.